

Is Uceris still in shortage in 2026? Get the latest update on Budesonide ER availability, pricing, and what you can do if your pharmacy is out of stock.
If you've been dealing with ulcerative colitis and relying on Uceris (Budesonide ER), you've probably experienced the frustration of hearing your pharmacy say they can't get it. The question on everyone's mind: Is the Uceris shortage finally over in 2026?
The short answer: it's better, but it's not fully resolved. Here's what you need to know.
The situation with Uceris has improved compared to the worst periods of 2022-2023, but availability remains inconsistent depending on where you live and which formulation you need.
Oral tablets (Budesonide ER 9 mg): Supply has improved modestly since 2024. Most regions have reasonable availability, but some areas still experience intermittent stockouts. Generic Budesonide ER from manufacturers like Teva has helped fill the gap.
Rectal foam (Budesonide 2 mg): This formulation has been hit harder and continues to be listed intermittently on the FDA drug shortage list. If you use the rectal foam, you may still face significant difficulty finding it.
The bottom line: the shortage isn't officially over, but the oral tablet is much more findable than it was two years ago — especially if you're open to the generic version.
Several factors have contributed to the ongoing availability challenges:
The global pharmaceutical supply chain has faced unprecedented pressure since 2022. Raw material sourcing, manufacturing capacity, and distribution logistics have all been strained. Budesonide products, which require specialized extended-release manufacturing, were particularly affected.
Unlike common generics produced by dozens of manufacturers, Budesonide ER tablets have a relatively small number of suppliers. When one manufacturer has an issue, the impact on overall supply is significant.
Even when nationwide supply is adequate, distribution isn't perfectly even. Some markets — often rural areas or smaller metro regions — receive less stock than major urban centers. This means your pharmacy in one city might have plenty while another 50 miles away has none.
High costs (brand Uceris runs $1,400 to $2,330 for 30 tablets) mean many pharmacies don't stock it proactively. They only order it when a patient brings in a prescription, which adds days to the process.
For a deeper dive into all the reasons behind the shortage, see our article on why Uceris is so hard to find.
Cost continues to be a major concern for patients. Here's where prices stand:
If cost is a barrier for you, our detailed guide on how to save money on Uceris walks through every savings option available.
The ulcerative colitis treatment landscape continues to evolve. While Uceris remains an important option, patients and doctors now have more choices than ever:
That said, for patients with mild to moderate UC who respond well to Budesonide, Uceris remains a valuable treatment. The key is being able to access it.
Here are the most effective strategies for locating Uceris today:
For a complete strategy guide, see our article on how to find Uceris in stock near you.
The Uceris shortage of 2022-2023 was one of the most frustrating medication access issues for UC patients. While things have gotten better in 2026, we're not out of the woods yet — especially for the rectal foam formulation.
The most important things you can do:
For comprehensive information about Uceris including dosage, side effects, and interactions, visit our guides on what is Uceris and Uceris side effects.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.